8 brokerages rate Spyre Therapeutics (NASDAQ:SYRE) as "Buy" with a $43.17 average target price.
8 brokerages covering Spyre Therapeutics (NASDAQ:SYRE) have a consensus rating of "Buy", with an average 12-month price target of $43.17. Analysts from Robert W. Baird, Stifel Nicolaus, and Wells Fargo & Co. have issued buy ratings and raised target prices for the company. BTIG Research set a $40.00 target price and a "buy" rating in a report on May 10th.
July 14, 2024
3 Articles